Novant Health Weisiger Cancer Insititute ( Site 4052) — Charlotte, North Carolina

Novant Health Weisiger Cancer Insititute ( Site 4052) is a clinical research site located in Charlotte, North Carolina, United States 28204.

Crixeo Clinical Trials Trust Score: 11/100 (FAILING). This profile has not yet been claimed by the site owner.

Novant Health Weisiger Cancer Insititute ( Site 4052) has participated in 2 clinical trials with 2 currently active.

Therapeutic areas: Non-small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung.

Sponsors: Merck Sharp & Dohme LLC.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Charlotte

Browse all research sites in North Carolina · View every site in Charlotte

Sponsor Feasibility Report

Trust Score: 11/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Novant Health Weisiger Cancer Insititute ( Site 4052)?

Novant Health Weisiger Cancer Insititute ( Site 4052) has a Crixeo Trust Score of 11/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Novant Health Weisiger Cancer Insititute ( Site 4052) conducted?

Novant Health Weisiger Cancer Insititute ( Site 4052) has 2 clinical trials on record, with 2 currently active. Their work covers Non-small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung.

Is Novant Health Weisiger Cancer Insititute ( Site 4052) accredited by Crixeo Clinical Trials?

Novant Health Weisiger Cancer Insititute ( Site 4052) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Novant Health Weisiger Cancer Insititute ( Site 4052)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.